Sentence examples for boosting scenario from inspiring English sources

The end results of this paper demonstrate the effectiveness of the proposed algorithm and satisfactory classification accuracies under several conditions such as different PMU reporting rates, different measurement noise levels, different number of PMUs, and boosting scenario.

All best-fitting parameter sets were based on boosting scenario 3 (predefined exponential loss of boosted VZV-CMI).

In scenarios with immune boosting (scenario A and C), there is a similarly strong increase in the ICER after approximately 20 years when health benefits caused by reduced VZV circulation are nullified by even stronger negative health effects caused by increasing HZ incidence.

The following 7 parameters were estimated by means of the fitting procedure: VZV-CMI waning rate, type of boosting scenario, duration of exogenous boosting, peak fold increase following exogenous boosting, VZV reactivation probability, FoR distribution and the peak fold increase following endogenous boosting.

Next, VZV-CMI will decrease following one of three different boosting scenarios (as shown in Figure 8) until it reaches the pre-boosting value again (after a 'duration of boosting'): Exponential decrease from peak to pre-boosting value based on VZV ELISPOT CMI data after Zostavax vaccination as published by Levin et al. (2008).

In order to quantify the impact of loss of functional imaging sensitivity and specificity on tumor control and normal tissue toxicity for selective boosting IMRT four selective boosting scenarios were designed: SB91-81 (EUD = 91 Gy for the high-risk tumor subvolume and EUD = 81 Gy for a remaining low-risk PTV (rPTV)), SB80-74, SB90-70, and risk-adaptive optimization.

10.7554/eLife.07116.014 Figure 8. Three different boosting scenarios.

Models without immune boosting (scenarios B and D) are characterised by health gains and limited costs or even savings, while models with immune boosting (scenarios A and C) are characterised by health losses and high costs.

In models without immune boosting (scenarios B and D), vaccination at high coverage is expected to be cost-effective (scenario D) or even cost-saving (scenario B).

In the long run, the mean age at HZ decreases by almost 10 years to persons in their fifties in scenarios with immune boosting (scenarios A and C).

In particular, in the three exogenous boosting scenarios, a number of parameters are simply assumed and no explanations on their values are provided.